重组痘苗载体疫苗(天坛)加强新型HBV亚单位疫苗在恒河猴中诱导更强更持久免疫
本研究在恒河猴中比较多种新型乙肝病毒(HBV)疫苗的初免-加强策略,包括HBV颗粒亚单位疫苗(HBSS1)及含S(1-223aa)和PreS1(21-47aa)的重组痘苗(RVJSS1)或腺病毒(rAdSS1)载体疫苗。纵向随访至接种后79周,发现HBSS1/RVJSS1异源初免-加强诱导体液免疫与HBSS1/HBSS1同源接种相似,但细胞免疫更强更持久;HBSS1/RVJSS1/RVJSS1诱导的细胞免疫比HBSS1/HBSS1/rAdSS1更强更持久。
要点
- HBSS1/RVJSS1异源初免-加强诱导体液免疫与HBSS1/HBSS1同源接种相似。
- HBSS1/RVJSS1异源初免-加强诱导的细胞免疫比HBSS1/HBSS1同源接种更强更持久。
- HBSS1/RVJSS1/RVJSS1诱导的细胞免疫比HBSS1/HBSS1/rAdSS1更强更持久。
核心结论
- HBSS1/RVJSS1/RVJSS1是保护人类免受HBV感染最有希望的候选方案,尤其适用于治疗性应用。
研究设计与样本
- 在恒河猴中开展纵向研究,比较多种新型HBV疫苗的初免-加强策略,随访至接种后79周。
- 测试疫苗包括HBV颗粒亚单位疫苗(HBSS1)及含S(1-223aa)和PreS1(21-47aa)的重组痘苗(RVJSS1)或腺病毒(rAdSS1)载体疫苗。
主要发现
- HBSS1/RVJSS1异源初免-加强诱导体液免疫与HBSS1/HBSS1同源接种相似,但细胞免疫比HBSS1/HBSS1更强更持久。
- HBSS1/RVJSS1/RVJSS1诱导的细胞免疫比HBSS1/HBSS1/rAdSS1更强更持久。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study explored several prime-boost strategies in rhesus macaques using various novel hepatitis B virus (HBV) vaccines that showed promise as prophylactic and therapeutic approaches in our previous study using in a mouse model. The tested vaccines included an HBV particle subunit (HBSS1) vaccine and the recombinant vaccinia (RVJSS1) or adenoviral (rAdSS1) vector-based vaccines containing S (1-223aa) and PreS1 (21-47aa). The strength and maintenance of humoral activity (IgG and neutralizing antibodies) and cellular immunity (interferon-γ production assessed by IFN-γ enzyme-linked immunosorbent spot (ELISpot) assay) were investigated in a longitudinal study following various vaccination protocols until 79weeks post-vaccination. We found that HBSS1/RVJSS1 heterologous prime-boost elicits similar strong humoral immunity but more robust and lasting cellular immunity (CMI) than HBSS1/HBSS1 homologous vaccination in rhesus macaques. Furthermore, HBSS1/RVJSS1/RVJSS1 induced more robust and lasting CMI in macaques than did HBSS1/HBSS1/rAdSS1 vaccination. Therefore, HBSS1/RVJSS1/RVJSS1 is most promising candidates for protecting humans against HBV infection, especially for therapeutic application.
引用
- Deng Y, Chuai X, Chen P, et al. Recombinant vaccinia vector-based vaccine (Tiantan) boosting a novel HBV subunit vaccine induced more robust and lasting immunity in rhesus macaques. Vaccine. 2017. PMID: 28487055. doi:10.1016/j.vaccine.2017.04.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。